Breeze Meds Review
GLP-1 clinic with rare oral and sublingual delivery options and a NAD+ longevity layer.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Quick Verdict
GLP-1 clinic with rare oral and sublingual delivery options and a NAD+ longevity layer.
Who it's for: Breeze Meds is best suited to readers who want to explore online GLP-1 access alongside a separate NAD+ option and are willing to verify final treatment details in the intake flow. It may be relevant to needle-averse buyers because it markets oral and sublingual options, but those formats require careful clinician discussion and should not be assumed equivalent to approved injectable treatment.
Bottom line: The landing page provides a useful starting price but not a full medication-by-dose plan matrix. That makes Breeze Meds a provider to compare only after you confirm the specific treatment, recurring billing, and total checkout cost. Brand-name shoppers should look at providers that publish FDA-approved medication pathways.
- Sublingual tirzepatide is rare in telehealth
- Flat-rate monthly pricing
- NAD+ longevity option in-house
- Compounded only, no brand-name option
- Public price detail is limited across medications and doses
- Oral or sublingual offers should not be presumed equivalent to approved injectables
Pros & Cons In Detail
Breeze Meds Pricing
Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at Breeze Meds.
| Program / Membership Fee | Not itemized on the public landing page |
| Medication Cost (From) | From $199 – $399/mo |
At the August 26, 2026 price check, BreezeMeds listed weight-loss injections from $199 and NAD+ injections from $169. Its public FAQ covers costs, insurance, delivery, clinicians, and pharmacy providers, but the landing page does not display a detailed medication-by-dose price matrix. Confirm treatment, dose, recurring billing, and any fees before checkout.
Who Breeze Meds Is For
Breeze Meds is best suited to readers who want to explore online GLP-1 access alongside a separate NAD+ option and are willing to verify final treatment details in the intake flow. It may be relevant to needle-averse buyers because it markets oral and sublingual options, but those formats require careful clinician discussion and should not be assumed equivalent to approved injectable treatment.
Needle-averse adults who want oral or sublingual GLP-1 options alongside NAD+ longevity injections.
Signature Programs
- ›Sublingual tirzepatide for needle-averse patients
- ›Oral semaglutide program
- ›NAD+ longevity injections
Medication Formulary
The Bottom Line
The landing page provides a useful starting price but not a full medication-by-dose plan matrix. That makes Breeze Meds a provider to compare only after you confirm the specific treatment, recurring billing, and total checkout cost. Brand-name shoppers should look at providers that publish FDA-approved medication pathways.
With an editor score of 4.3 / 5 across cost, experience, and trust, Breeze Meds is one of the strong mid-tier options in the glp-1 weight loss category we cover.
See how Breeze Meds compares in our full glp-1 weight loss rankings, or read the Best Telehealth GLP-1 Providers guide. Our methodology explains how we score each provider.
Frequently Asked Questions
- Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks in the STEP 1 trial.
- FDA Federal Register 2024 (Semaglutide shortage end) · FDA removed semaglutide from the drug shortage list in October 2024, ending the legal basis for compounding.
- Jastreboff et al., NEJM 2022 (SURMOUNT-1) · Tirzepatide 15 mg produced 20.9% mean weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1.
- FDA Federal Register 2024 (Tirzepatide shortage end) · FDA removed tirzepatide from the drug shortage list in October 2024.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
